Annuncio pubblicitario
Italia markets close in 7 hours 46 minutes

  • FTSE MIB

    34.155,49
    -115,63 (-0,34%)
     

  • Dow Jones

    38.460,92
    -42,77 (-0,11%)
     

  • Nasdaq

    15.712,75
    +16,11 (+0,10%)
     

  • Nikkei 225

    37.628,48
    -831,60 (-2,16%)
     

  • Petrolio

    82,97
    +0,16 (+0,19%)
     

  • Bitcoin EUR

    59.683,01
    -2.584,82 (-4,15%)
     

  • CMC Crypto 200

    1.389,55
    +6,98 (+0,50%)
     

  • Oro

    2.335,00
    -3,40 (-0,15%)
     

  • EUR/USD

    1,0719
    +0,0018 (+0,17%)
     

  • S&P 500

    5.071,63
    +1,08 (+0,02%)
     

  • HANG SENG

    17.263,71
    +62,44 (+0,36%)
     

  • Euro Stoxx 50

    4.965,28
    -24,60 (-0,49%)
     

  • EUR/GBP

    0,8575
    -0,0008 (-0,10%)
     

  • EUR/CHF

    0,9785
    +0,0001 (+0,01%)
     

  • EUR/CAD

    1,4660
    +0,0004 (+0,03%)
     

Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference

Editas Medicine, Inc.
·1 minuto per la lettura

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at the 40th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 12, 2022, at 10:30 a.m. ET

A live webcast of the presentation will be available on the Investors section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available on the website for approximately 30 days following the presentation.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts:
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

Investors
Ron Moldaver
(617) 401-9052
ir@editasmed.com